SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/18/2017 2:08:56 PM - Followers: 64 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GALT News: Current Report Filing (8-k) 02/17/2017 04:34:12 PM
GALT News: Galectin Therapeutics to Present at BIO CEO & Investor Conference 02/08/2017 08:30:00 AM
GALT News: Current Report Filing (8-k) 02/07/2017 04:40:18 PM
GALT News: Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Pha... 02/07/2017 04:40:00 PM
GALT News: Current Report Filing (8-k) 02/02/2017 11:06:37 AM
PostSubject
#2877   And before a stock market holiday Monday! gss2003 02/18/17 02:08:56 PM
#2876   I learned a long time ago that any biotech2010 02/17/17 11:49:26 PM
#2875   My guess is that there will be a Oddjob 02/17/17 08:10:45 PM
#2874   If I understand correctly they are only changing jmh0602 02/17/17 05:59:53 PM
#2873   If I understand correctly they are only changing jmh0602 02/17/17 05:59:51 PM
#2872   I''m think this is tied to a partnership. gss2003 02/17/17 05:43:18 PM
#2871   http://investor.galectintherapeutics.com/secfiling.cfm?filingid=1193125-17-48038 Seagrass 02/17/17 05:31:38 PM
#2870   I know there was a release but really gss2003 02/17/17 05:30:25 PM
#2869   Anybody notice the 8K with the shares just posted Seagrass 02/17/17 05:25:31 PM
#2868   Interesting would it make sense for a BMY or gss2003 02/17/17 05:19:31 PM
#2867   A buyout would be much much higher. Chess Master 02/17/17 04:56:42 PM
#2866   The key is look at the before and Chess Master 02/17/17 04:49:55 PM
#2865   I would think $6-7 on a buyout? goingforittoday 02/17/17 02:36:04 PM
#2864   Pretty impressive story... goingforittoday 02/17/17 02:34:47 PM
#2863   Need the partnership for this, hopefully the process gss2003 02/17/17 11:58:07 AM
#2862   Now you get it. That SA article really Chess Master 02/17/17 11:39:50 AM
#2861   You betcha! biotech2010 02/16/17 12:29:56 AM
#2860   I am just digging into this recently and Tekterra 02/15/17 05:42:33 PM
#2859   CONCLUSION Here we have strived to present the role staccani 02/15/17 09:43:33 AM
#2858   I really appreciate both of your inputs, this biotech2010 02/15/17 09:13:04 AM
#2857   Sorry but I encourage you to do some staccani 02/15/17 09:05:44 AM
#2856   Look the CX is fine. They will Chess Master 02/15/17 08:53:09 AM
#2855   I think GALT CX trial will fail as staccani 02/15/17 07:55:57 AM
#2854   Thanks for info. Coolec78 02/14/17 11:56:59 PM
#2853   They have a Phase 2 trial for Cirrhosis biotech2010 02/14/17 11:40:08 PM
#2852   What's good entry point on cnat? Any catalyst Coolec78 02/14/17 10:14:08 PM
#2851   I won't disagree with you on that, it's biotech2010 02/14/17 09:48:18 PM
#2850   1,255,000 short as of Jan 31. Today's action jmh0602 02/14/17 08:14:15 PM
#2849   Wonder how many are short. Could be a Darwinian 02/14/17 07:21:01 PM
#2848   Look for a gap up tomorrow. The Chess Master 02/14/17 06:38:17 PM
#2847   1.8 that's too much. Something is cooking. Coolec78 02/14/17 04:29:38 PM
#2846   Yes, but maybe GALT is asking a lot gss2003 02/14/17 03:31:50 PM
#2845   Not necessarily. Now they can buy GALT cheap Coolec78 02/14/17 03:24:06 PM
#2844   It also can be takeover if you guys Coolec78 02/14/17 03:06:26 PM
#2843   I think the only news of consequence that IRAHopeful 02/14/17 02:53:45 PM
#2842   Look you guys can be bitter all you Chess Master 02/14/17 02:08:01 PM
#2841   strange trading indeed. CNAT down, GALT up 20%. jmh0602 02/14/17 02:01:24 PM
#2840   GALT Moving .... stock1ace1 02/14/17 01:26:47 PM
#2839   If you watched the presentation yesterday the answer biotech2010 02/14/17 09:24:22 AM
#2838   Can we expect any news, anything before december??? Coolec78 02/14/17 09:09:16 AM
#2837   Maybe, after all f ups, good product will Coolec78 02/13/17 10:19:50 PM
#2836   I hold much less GALT and more CNAT biotech2010 02/13/17 03:47:22 PM
#2835   I hold lots of both. gss2003 02/13/17 03:44:07 PM
#2834   After watching the CNAT presentation today I wonder biotech2010 02/13/17 02:53:07 PM
#2833   Another SA article talking about Immuno results and gss2003 02/09/17 11:41:50 AM
#2832   All OGXI trials had failed, and so far Coolec78 02/09/17 10:18:38 AM
#2831   Yup. Then biotech2010 explains something there is nothing Coolec78 02/09/17 10:13:15 AM
#2830   There is a big difference between an unproven biotech2010 02/09/17 03:47:20 AM
#2829   We BELIEVE it works. Let's don't pump our Coolec78 02/09/17 12:42:09 AM
#2828   Look we know it works. Just look Chess Master 02/08/17 10:02:47 PM
PostSubject